Amelenodor
NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn's disease and ulcerative colitis[1][2].
Product Specifications
CAS Number
2389235-01-0
Product Name Alternative
NX-13
UNSPSC
12352005
Target
NOD-like Receptor (NLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/nx-13.html
Purity
98.11
Solubility
DMSO : 135 mg/mL (ultrasonic; warming)
Smiles
CC1=NC(OC2=CC(OC3=CC=CC(C)=N3)=CC(OC4=CC=CC(C)=N4)=C2)=CC=C1
Molecular Formula
C24H21N3O3
Molecular Weight
399.44
References & Citations
[1]Leber A, et.al. Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1 [published online ahead of print, 2019 Oct 25]. Drug Chem Toxicol. 2019;1-6.|[2]Leber A, et al. Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4+ T Cells. J Immunol. 2019;203 (12) :3407-3415.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
R0495-03A-ML750 100 µL
RAF-1, phosphorylated (Ser233) (RAF Proto-Oncogene Serine/Threonine-Protein Kinase, Proto-Oncogene c-RAF, cRaf, RAF1, RAF) (MaxLight 750) discontinued
Sign In for Pricing
View Details 
